Here we demonstrate the effectiveness and molecular mechanisms of the potent and selective ATP-competitive small-molecule inhibitor of WEE1 adavosertib (also known as AZD1775 or MK-1775) in ALL, including ALL specimens bearing TP53 and other prognostically poor genetic alterations. Here, WEE1 is linked to acute lymphoblastic leukemia.